Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

New on Charts:

We've added Splits, Dividends, Earnings, and Earnings Estimates! Click on individual events to unveil more details.

If you prefer a cleaner view, easily disable them in Settings.

ESLA | Estrella Biopharma Inc

Index- P/E- EPS (ttm)-0.18 Insider Own61.20% Shs Outstand2.33M Perf Week-72.99%
Market Cap6.40M Forward P/E- EPS next Y- Insider Trans0.00% Shs Float0.84M Perf Month-76.81%
Income-0.63M PEG- EPS next Q- Inst Own34.82% Short Float / Ratio1.28% / 0.02 Perf Quarter-72.91%
Sales0.00M P/S- EPS this Y- Inst Trans1.51% Short Interest0.01M Perf Half Y-70.91%
Book/sh2.97 P/B0.99 EPS next Y- ROA-2.28% Target Price- Perf Year-70.20%
Cash/sh0.01 P/C213.38 EPS next 5Y- ROE-2.51% 52W Range2.79 - 33.00 Perf YTD-71.33%
Dividend- P/FCF- EPS past 5Y- ROI-9.16% 52W High-91.06% Beta0.05
Dividend %- Quick Ratio0.09 Sales past 5Y0.00% Gross Margin- 52W Low5.64% ATR3.25
Employees- Current Ratio0.09 Sales Q/Q- Oper. Margin0.00% RSI (14)36.93 Volatility43.62% 34.67%
OptionableNo Debt/Eq0.13 EPS Q/Q46.99% Profit Margin- Rel Volume1.21 Prev Close2.85
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume495.93K Price2.95
Recom- SMA20-70.43% SMA50-69.28% SMA200-70.96% Volume598,928 Change3.51%
Estrella Immunopharma, Inc. operates as a pre-clinical stage biopharmaceutical company, which engages in the development of T-cell therapies with the capacity to address treatment and safety challenges for patients with blood cancers and solid tumors. The company is headquartered in Wilmington, DE.